JO2359B1 - Benzathene derivatives as agents for modulation of GABA A receptor - Google Patents

Benzathene derivatives as agents for modulation of GABA A receptor

Info

Publication number
JO2359B1
JO2359B1 JO2001183A JOP20010183A JO2359B1 JO 2359 B1 JO2359 B1 JO 2359B1 JO 2001183 A JO2001183 A JO 2001183A JO P20010183 A JOP20010183 A JO P20010183A JO 2359 B1 JO2359 B1 JO 2359B1
Authority
JO
Jordan
Prior art keywords
gaba
receptor modulators
benzodiazepine derivatives
receptor
compounds
Prior art date
Application number
JO2001183A
Other languages
Arabic (ar)
English (en)
Inventor
ماسيادري رافيللو
ويليام ثوماس اندرو
ويتشمان جيورجن
Original Assignee
اف . هوفمان- لاروش أيه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان- لاروش أيه جي filed Critical اف . هوفمان- لاروش أيه جي
Application granted granted Critical
Publication of JO2359B1 publication Critical patent/JO2359B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JO2001183A 2000-11-16 2001-11-12 Benzathene derivatives as agents for modulation of GABA A receptor JO2359B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00124332 2000-11-16

Publications (1)

Publication Number Publication Date
JO2359B1 true JO2359B1 (en) 2006-12-12

Family

ID=8170315

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2001183A JO2359B1 (en) 2000-11-16 2001-11-12 Benzathene derivatives as agents for modulation of GABA A receptor

Country Status (40)

Country Link
US (1) US6743789B2 (enExample)
EP (1) EP1337535B1 (enExample)
JP (1) JP4088151B2 (enExample)
KR (1) KR100504300B1 (enExample)
CN (1) CN1191255C (enExample)
AR (1) AR031345A1 (enExample)
AT (1) ATE268776T1 (enExample)
AU (2) AU1700702A (enExample)
BG (1) BG107817A (enExample)
BR (1) BR0115393A (enExample)
CA (1) CA2427576C (enExample)
CZ (1) CZ295256B6 (enExample)
DE (1) DE60103776T2 (enExample)
DK (1) DK1337535T3 (enExample)
EC (1) ECSP034607A (enExample)
ES (1) ES2220831T3 (enExample)
GC (1) GC0000375A (enExample)
GT (1) GT200100230A (enExample)
HR (1) HRP20030360A2 (enExample)
HU (1) HUP0303281A3 (enExample)
IL (1) IL155813A0 (enExample)
JO (1) JO2359B1 (enExample)
MA (1) MA26962A1 (enExample)
MX (1) MXPA03004251A (enExample)
MY (1) MY141675A (enExample)
NO (1) NO324706B1 (enExample)
NZ (1) NZ525413A (enExample)
PA (1) PA8532401A1 (enExample)
PE (1) PE20020583A1 (enExample)
PL (1) PL362925A1 (enExample)
PT (1) PT1337535E (enExample)
RU (1) RU2278865C2 (enExample)
SI (1) SI1337535T1 (enExample)
SK (1) SK7232003A3 (enExample)
TR (1) TR200402073T4 (enExample)
TW (1) TWI239333B (enExample)
UY (1) UY27026A1 (enExample)
WO (1) WO2002040487A2 (enExample)
YU (1) YU35603A (enExample)
ZA (1) ZA200303435B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US7626029B2 (en) * 2003-06-19 2009-12-01 Daiichi Pharmaceutical Co., Ltd. Method of selectively introducing amino substituent
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1784390A2 (en) 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
ATE402707T1 (de) 2004-10-12 2008-08-15 Hoffmann La Roche Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen
NZ554439A (en) * 2004-10-20 2009-09-25 Hoffmann La Roche Imidazo-benzodiazepine derivatives
RU2007114763A (ru) * 2004-10-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) Галогенозамещенные производные бензодиазепинов
WO2006063708A1 (en) 2004-12-14 2006-06-22 F.Hoffmann-La Roche Ag Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
EP1924712B1 (en) * 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
JP4885967B2 (ja) * 2005-10-11 2012-02-29 エフ．ホフマン−ラ ロシュ アーゲー イミダゾベンゾジアゼピン誘導体
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
PE20110590A1 (es) 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
BRPI0922303B1 (pt) * 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
CU20090172A7 (es) 2009-10-09 2011-10-05 Ct De Investigación Y Desarrollo De Medicamentos Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2885148A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
EP4032889B1 (en) * 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (en) * 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10059718B2 (en) * 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
US10973479B2 (en) 2016-05-16 2021-04-13 Canon Medical Systems Corporation X-ray diagnosis apparatus, X-ray diagnosis apparatus controlling method, and X-ray diagnosis system
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102151969B1 (ko) * 2019-12-11 2020-09-04 주식회사 지투비 투과도 가변창의 제조방법 및 그에 의해 제조된 투과도 가변창
CN112979658B (zh) * 2021-02-22 2022-05-31 南湖实验室 一种氟马西尼的制备方法
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174086D0 (da) 1986-04-16 1986-04-16 Ferrosan As Nye benzodiazepinderivater samt fremgangsmaade til fremstilling af samme
TW201311B (enExample) 1991-06-17 1993-03-01 Hoffmann La Roche

Also Published As

Publication number Publication date
EP1337535A2 (en) 2003-08-27
DK1337535T3 (da) 2004-10-25
US6743789B2 (en) 2004-06-01
HK1062442A1 (en) 2004-11-05
ES2220831T3 (es) 2004-12-16
IL155813A0 (en) 2003-12-23
BR0115393A (pt) 2004-07-06
DE60103776D1 (de) 2004-07-15
HUP0303281A2 (hu) 2004-01-28
HRP20030360A2 (en) 2005-04-30
KR100504300B1 (ko) 2005-07-28
SK7232003A3 (en) 2004-03-02
EP1337535B1 (en) 2004-06-09
MA26962A1 (fr) 2004-12-20
NO324706B1 (no) 2007-12-03
CN1191255C (zh) 2005-03-02
DE60103776T2 (de) 2005-07-14
KR20030045192A (ko) 2003-06-09
HUP0303281A3 (en) 2005-05-30
YU35603A (sh) 2006-05-25
TWI239333B (en) 2005-09-11
NZ525413A (en) 2005-02-25
TR200402073T4 (tr) 2004-10-21
GC0000375A (en) 2007-03-31
MXPA03004251A (es) 2003-09-22
WO2002040487A2 (en) 2002-05-23
JP2004517070A (ja) 2004-06-10
PT1337535E (pt) 2004-09-30
PL362925A1 (en) 2004-11-02
NO20032208L (no) 2003-05-15
ECSP034607A (es) 2003-06-25
AU2002217007B2 (en) 2006-11-30
US20020103371A1 (en) 2002-08-01
BG107817A (bg) 2004-07-30
NO20032208D0 (no) 2003-05-15
CA2427576A1 (en) 2002-05-23
CA2427576C (en) 2007-11-06
UY27026A1 (es) 2002-06-20
CN1474820A (zh) 2004-02-11
MY141675A (en) 2010-06-15
AR031345A1 (es) 2003-09-17
CZ295256B6 (cs) 2005-06-15
CZ20031597A3 (cs) 2003-11-12
PE20020583A1 (es) 2002-07-06
GT200100230A (es) 2002-07-04
PA8532401A1 (es) 2002-08-26
ATE268776T1 (de) 2004-06-15
RU2278865C2 (ru) 2006-06-27
AU1700702A (en) 2002-05-27
RU2003116895A (ru) 2005-02-20
WO2002040487A3 (en) 2002-09-26
JP4088151B2 (ja) 2008-05-21
SI1337535T1 (en) 2004-10-31
ZA200303435B (en) 2004-08-05

Similar Documents

Publication Publication Date Title
AU3652102A (en) Compounds and their uses
BG103870A (en) Substituted benzopyran derivatives for the treatment of inflammations
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
AU5242000A (en) Nematicidal trifluorobutenes
BG102976A (en) Method for the preparation of drospyrenon (6 beta,7 beta: 15 beta,16 beta - dimethylene-3-oxo-17 alpha -pregn-4-ene-21,17-carbolacton, drsp)as well as 7 alpha-(3-hydroxy-1-propyl)-(6 beta,7 beta: 15 beta,16 beta -dirmethylene-5 beta-androstan-3 beta,5,17 beta -triol (zk 92836) and (6 beta,7 beta: 15 beta,16 beta - dimethylene-5 beta-hydroxy-3-oxo-17 alpha -androstan-21, 17-carbolacton (90965) as intermediate compounds of the method
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
EP0911321A3 (en) Compounds for the treatment of osteoporosis
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
AU2001269063A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
BG105197A (en) Polymorph form of a medicament
MY133390A (en) Azabicyclic 5ht1 receptor ligands
UA66866C2 (uk) Синтез морфолінових похідних
BG103649A (en) Method for the preparation of eprosartan
AU7216498A (en) Inhibitors of the urokinase receptor
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
BG103650A (en) Method for the preparation of eprosartan
BG102229A (en) Endothelium receptor antagonists
AU2002336437A1 (en) Therapeutic uses of complement receptor 2
WO2001062765A3 (en) Small molecule modulators of g protein-coupled receptor six
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.